Samiksha Jaiswal (Editor)


Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
ATC code  None
CAS Number  331741-94-7
ChemSpider  178524
Legal status  Development terminated
PubChem CID  206044
Molar mass  516.54 g/mol
Muraglitazar httpsuploadwikimediaorgwikipediacommonsthu
Synonyms  2-[(4-Methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid

How to pronounce muraglitazar

Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARĪ± and PPARĪ³.

The drug had completed phase III clinical trials, however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development.

Data on muraglitazar is relatively sparse due to the recent introduction of this agent. One double-blind randomized clinical trial comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA1c (p <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. A meta-analysis of the phase II and III clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and congestive heart failure (CHF) when compared to placebo or pioglitazone.


Muraglitazar Wikipedia

Similar Topics
Emanuele Bardelloni
Myint Naing